5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

Margaret G. Mcglynn net worth and biography

Margaret Mcglynn Biography and Net Worth

Director of Amicus Therapeutics

Margaret G. McGlynn has served as a member of our Board since October 2009. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as CEO and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Board of Directors of Vertex Pharmaceuticals, Inc. and of Novavax, Inc. She also serves on the Board of Buffalo BioNet Advisory Group (private) and the Board of the Advisory Committee, UB School of Pharmacy (private). Previously, she served on the Boards of Air Products and Chemicals, Inc. and Orphan Technologies. She is also Chair of the Board of HCU Network America, a non‑profit which provides advocacy and support research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.

Ms. McGlynn serves as chair of the Compensation and Leadership Development Committee and as member of the Nominating and Governance Committee.

What is Margaret G. Mcglynn's net worth?: The estimated net worth of Margaret G. Mcglynn is at least $612,455.37 as of March 5th, 2024. Ms. Mcglynn owns 59,289 shares of Amicus Therapeutics stock worth more than $612,455 as of April 18th. This net worth approximation does not reflect any other assets that Ms. Mcglynn may own. Learn More about Margaret G. Mcglynn's net worth.
How do I contact Margaret G. Mcglynn?: The corporate mailing address for Ms. Mcglynn and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Margaret G. Mcglynn's contact information.
Has Margaret G. Mcglynn been buying or selling shares of Amicus Therapeutics?: Margaret G. Mcglynn has not been actively trading shares of Amicus Therapeutics during the last quarter. Most recently, Margaret G. Mcglynn sold 7,500 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.40, for a transaction totalling $100,500.00. Following the completion of the sale, the director now directly owns 59,289 shares of the company's stock, valued at $794,472.60. Learn More on Margaret G. Mcglynn's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 42 times. They sold a total of 526,511 shares worth more than $6,805,375.39. The most recent insider tranaction occured on March, 5th when Director Margaret G Mcglynn sold 7,500 shares worth more than $100,500.00. Insiders at Amicus Therapeutics own 2.1% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 3/5/2024.

Margaret G. Mcglynn Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2024	Sell	7,500	$13.40	$100,500.00	59,289
1/13/2023	Sell	15,000	$13.03	$195,450.00	50,705
5/2/2022	Sell	15,000	$6.99	$104,850.00	38,034
5/3/2021	Sell	10,000	$10.27	$102,700.00	37,919
4/17/2020	Sell	10,000	$11.00	$110,000.00	32,064
1/9/2020	Sell	20,000	$10.00	$200,000.00	42,064
5/16/2018	Sell	10,000	$16.00	$160,000.00	25,814
11/10/2015	Buy	10,000	$10.27	$102,700.00	10,000

Margaret G. Mcglynn Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $10.33

$10.32

$10.59

50 Day Range

MA: $12.24

$10.33

$14.00

2 Week Range

Now: $10.33

$9.70

$14.57

Volume

1,725,749 shs

Average Volume

3,009,370 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

The #1 Crypto for 2024

From InvestorPlace | Ad